VRTX icon

Vertex Pharmaceuticals

421.16 USD
-10.84
2.51%
At close May 14, 4:00 PM EDT
After hours
418.03
-3.13
0.74%
1 day
-2.51%
5 days
-2.09%
1 month
-15.06%
3 months
-8.24%
6 months
-12.98%
Year to date
3.80%
1 year
-1.73%
5 years
52.04%
10 years
242.41%
 

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 191 | Existing positions closed: 154

11% more call options, than puts

Call options by funds: $780M | Put options by funds: $700M

2.03% more ownership

Funds ownership: 89.52% [Q3] → 91.54% (+2.03%) [Q4]

0% more funds holding

Funds holding: 1,526 [Q3] → 1,529 (+3) [Q4]

10% less repeat investments, than reductions

Existing positions increased: 546 | Existing positions reduced: 605

11% less capital invested

Capital invested by funds: $107B [Q3] → $95.5B (-$11.8B) [Q4]

45% less funds holding in top 10

Funds holding in top 10: 29 [Q3] → 16 (-13) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$423
0%
upside
Avg. target
$493
17%
upside
High target
$567
35%
upside

7 analyst ratings

positive
43%
neutral
57%
negative
0%
RBC Capital
Brian Abrahams
20% 1-year accuracy
15 / 74 met price target
0%upside
$423
Sector Perform
Maintained
6 May 2025
Scotiabank
Greg Harrison
32% 1-year accuracy
13 / 41 met price target
5%upside
$442
Sector Perform
Maintained
6 May 2025
Morgan Stanley
Matthew Harrison
26% 1-year accuracy
6 / 23 met price target
10%upside
$464
Equal-Weight
Maintained
6 May 2025
JP Morgan
Jessica Fye
46% 1-year accuracy
19 / 41 met price target
22%upside
$515
Overweight
Maintained
6 May 2025
Cantor Fitzgerald
Carter Gould
29% 1-year accuracy
9 / 31 met price target
27%upside
$535
Overweight
Reiterated
6 May 2025

Financial journalist opinion

Based on 50 articles about VRTX published over the past 30 days

Neutral
MarketBeat
1 day ago
Best Biotech Stocks to Buy in 2025
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
Best Biotech Stocks to Buy in 2025
Positive
The Motley Fool
1 day ago
2 Biotech Stocks That Are Screaming Buys in May
It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself up for a bigger win if you look to quality companies that have seen their stocks stumble in recent times.
2 Biotech Stocks That Are Screaming Buys in May
Positive
The Motley Fool
1 day ago
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next
Vertex Pharmaceuticals (VRTX 3.40%), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the market's liking, so much so that they led to a significant post-earnings dip for the stock.
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next
Positive
The Motley Fool
2 days ago
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance by buying shares of companies likely to beat broader equities.
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Neutral
The Motley Fool
4 days ago
My Favorite Tariff Safe-Haven Stock to Buy on the Dip
Uncertainty has weighed on stocks over the past several weeks, pushing the three major indexes lower -- the S&P 500 (^GSPC -0.07%) even temporarily slid into a bear market. What's driven this negative momentum is investors' concerns about the potential impact of import tariffs on corporate earnings.
My Favorite Tariff Safe-Haven Stock to Buy on the Dip
Neutral
CNBC Television
5 days ago
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
Positive
Zacks Investment Research
5 days ago
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Neutral
The Motley Fool
5 days ago
4 No-Brainer Stocks to Buy Right Now
Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even in the current environment, there are excellent investment opportunities.
4 No-Brainer Stocks to Buy Right Now
Negative
Zacks Investment Research
1 week ago
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Positive
The Motley Fool
1 week ago
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date.
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Charts implemented using Lightweight Charts™